Skyrizi (Risankizumab) Insurance Denial Appeal Guide

Skyrizi (risankizumab) is an IL-23 inhibitor approved for plaque psoriasis, psoriatic arthritis, and Crohn's disease. Its high efficacy and convenient dosing (every 12 weeks for psoriasis) make it a preferred option, but step therapy requirements are common.

FDA-Approved Indications

  • Moderate-to-severe plaque psoriasis (adults)
  • Active psoriatic arthritis (adults)
  • Moderate-to-severe Crohn's disease (adults)

Appeal Strategy

  1. Document failure/intolerance of required step therapy medications
  2. Cite IMMhance and KEEPsAKE trial data
  3. PASI 90/100 response rates (superior to many competitors)
  4. Dermatologist or gastroenterologist letter
  5. IL-23 mechanism advantages over TNF inhibitors
  6. Convenient every-12-week dosing improves adherence

Need Help Writing Your Appeal?

Our AI-powered tool analyzes your denial letter and generates a personalized appeal in minutes. Upload your denial and get started for free.

Start Your Free Appeal

Frequently Asked Questions

Is Skyrizi better than Humira for psoriasis?

Clinical trials (IMMvent) showed Skyrizi achieved higher skin clearance rates (PASI 90) compared to Humira for plaque psoriasis. However, individual responses vary, and your dermatologist should determine the best biologic based on your specific situation and medical history.

Related Resources